

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/415,890		10/08/1999	BORJE S. ANDERSSON	UTXC:5281	5425	
32425	7590	05/15/2006		EXAMINER		
		WORSKI L.L.P.		LEVY, NEIL S  ART UNIT PAPER NUMBER		
600 CONGI		3.				
SUITE 2400 AUSTIN, T	-					
AUSTIN, I	76701					
				DATE MAILED: 05/15/200	DATE MAILED: 05/15/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/415,890	ANDERSSON, BORJE	S.				
Office Action Summary	Examiner	Art Unit					
	NEIL LEVY	1615					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	S				
• •	/ IO OET TO EVENE - MONTH	0) 00 THURTY (00) D					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period v  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communi 0 (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 3/31/	706 by the Roard of Anneals						
· · · · · · · · · · · · · · · · · · ·	action is non-final.						
3) Since this application is in condition for allowar		secution as to the mer	ite ie				
closed in accordance with the practice under E	•		110 10				
Disposition of Claims	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
4) Claim(s) <u>94-97,99 and 106-150</u> is/are pending	in the application						
4a) Of the above claim(s) <u>94-96,106-115,123-1</u>	• •	vithdrawn from conside	ration				
5) Claim(s) is/are allowed.	<del></del>	maram morn consider	ration.				
6) Claim(s) <u>97,99,116,117,119,121,122 and 133</u> i	s/are rejected						
7) Claim(s) <u>118,120,134-137,142,143,150</u> is/are of	<u> </u>						
8) Claim(s) <u>94-97 and 106-150</u> are subject to rest	•	nt.					
Application Papers							
_							
9) The specification is objected to by the Examine							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
			10471				
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex							
	ammer. Note the attached Office	Action of form PTO-15	02.				
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).					
1. Certified copies of the priority documents	s have been received.						
2. Certified copies of the priority documents		on No					
3. Copies of the certified copies of the prior			е				
application from the International Bureau	(PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list	of the certified copies not receive	d.					
			•				
Attachment(s)							
Notice of References Cited (PTO-892)	4) Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te atent Application (PTO-152)					
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6)  Other:	жент аррисации (*10-192)					

**Art Unit: 1615** 

### **DETAILED ACTION**

This case has been returned to the examiner by The Board of Appeals.

#### Election/Restrictions

Claims 94-96,106-115,`123-132,138-140 & 144-149 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention & secies, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on paper # 19.

Claim118, 120, 134-137, 141,142, 143, 150are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims

## Claim Rejections - 35 USC § 103

Claim97, 99, 116, 117, 119 are rejected under 35 U.S.C. 103(a) as being unpatentable over Janoff et al 6405713

Janoff's other method (column 11, last paragraph; column 12, top) selects a solvent and drug and mixes with a lipid solution and bufferred aqueous solution, (PBS) steps – a& b----of claim 97; then evaporates off the solvent (step c); evaporation would remove all solvent, thus less than 50%. This is followed by adding PBS (step d). The difference from claim 97, is a drug is present. Under comprising language, it is permitted, and 99 is pimaricin added-Janoff adds pimaricin as the first specified polyene antibiotic (column 9, lines 37, 38) thus obvious to the artisan to involve the specified agents in column 9, as the exemplified drug in column 11. The instant claim 116 is to a lipid solution; so is Janoff's other method (column 11, line 60.)

Preparation includes -sonification-of the DMPC:DMPG in solution, thus, the result can comprise an aqueous-lipid emulsion, also of claim 117, or water (claim 116) as, again, open language is used. Soy as a lipid emulsion source is disclosed at column 8, lines 66, 67.

Art Unit: 1615

1. Claim97, 99, 116, 117, 119, 133 are rejected under 35 U.S.C. 103(a) as being unpatentable over Janoff et al 6405713 in view of SZOKA, Jr. 527914.

Janoff (above) utilizes any number of aprotic solvents in methods of preparing pharmaceutically acceptable solvent vehicles, but does NOT mention applicant's equivalent to DMSO, DMA. However, SZOKA shows this equivalency (column 5, lines 8-13) in preparing stable parenteral suspensions (column 6, lines 13-15) of amphotericin, nystatin, and primaricin (column 6, lines 44, 45).

# .Double Patenting

Claims97, 99, 116, 119, 121, 122, 133 are ------provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim s 45-63 of copending Application No. 10/439252. Although the conflicting claims are not identical, they are not patentably distinct from each other because The same composition is prepared in the manner of the instant, as the composition instantly obtained by the instant methods.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, MICHAEL WOODWARD can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/415,890 Page 4

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

NEIL LEVY Primary Examiner Art Unit 1615

\*\*\*